Gain Therapeutics
GANX· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +49.1% in FY2025
Gene Mack is the CEO of Gain Therapeutics and was paid $1.5M in FY2025 (Dec), up 99%.
Pay$100 in the stock at the end of FY22 → $103
Executives2
See all- 1Gene MackChief Executive OfficerFY2025
- 2Gianluca FuggettaPrincipal Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allGain Therapeutics paid its 2 named executives $1.8M in total in FY2025 (Dec). CEO Gene Mack was paid $1.5M of that.
| Name | |||
|---|---|---|---|
| Gene MackChief Executive Officer | |||
| Gianluca FuggettaPrincipal Financial Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Gain Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board4
See all- Jeffrey RileyDirector · 6 yr on the boardIndependentAudit, Compensation (Chair)—Paid as an executive
- Claude Nicaise, M.D.Director · 4 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive
- Dov Goldstein, M.D.Director · 4 yr on the boardIndependentAudit (Chair), Nominating and Corporate Governance—Paid as an executive
- Gwen MelincoffDirector · 4 yr on the boardIndependentCompensation—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 28, 2026 | FY2025 |
| Annual report | 10-K | Mar 26, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 29, 2025 | FY2024 |
| Annual report | 10-K | Mar 27, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Mar 26, 2024 | FY2023 |
